Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Linear and circular CDKN2B-AS1 expression is associated with Inflammatory Bowel Disease and participates in intestinal barrier formation.

Rankin CR, Lokhandwala ZA, Huang R, Pekow J, Pothoulakis C, Padua D.

Life Sci. 2019 Aug 15;231:116571. doi: 10.1016/j.lfs.2019.116571. Epub 2019 Jun 14.

2.

Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis.

Ollech JE, Rubin DT, Glick L, Weisshof R, El Jurdi K, Israel A, Krugliak Cleveland N, Hyman N, Sakuraba A, Pekow J, Cohen RD, Dalal SR.

Dig Dis Sci. 2019 Jun 11. doi: 10.1007/s10620-019-05697-1. [Epub ahead of print]

PMID:
31187322
3.

Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.

Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A.

J Gastroenterol Hepatol. 2019 Jun 6. doi: 10.1111/jgh.14751. [Epub ahead of print]

PMID:
31169926
4.

Challenges in IBD Research: Pragmatic Clinical Research.

Scott FI, Rubin DT, Kugathasan S, Bousvaros A, Elson CO, Newberry RD, Melmed GY, Pekow J, Fleshman JW, Boyle BM, Mahadevan U, Cannon LM, Long MD, Cross RK, Ha CY, Lasch KL, Robinson AM, Rafferty JF, Lee JJ, Dahl KDC, Weaver A, Shtraizent N, Honig G, Hurtado-Lorenzo A, Heller CA.

Inflamm Bowel Dis. 2019 May 16;25(Supplement_2):S40-S47. doi: 10.1093/ibd/izz085.

PMID:
31095704
5.

Losartan and Vitamin D Inhibit Colonic Tumor Development in a Conditional Apc-Deleted Mouse Model of Sporadic Colon Cancer.

Dougherty U, Mustafi R, Haider HI, Khalil A, Souris JS, Joseph L, Hart J, Konda VJ, Zhang W, Pekow J, Li YC, Bissonnette M.

Cancer Prev Res (Phila). 2019 Jul;12(7):433-448. doi: 10.1158/1940-6207.CAPR-18-0380. Epub 2019 May 14.

PMID:
31088824
6.

Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers.

Alpert L, Yassan L, Poon R, Kadri S, Niu N, Patil SA, Mujacic I, Montes D, Galbo F, Wurst MN, Zhen CJ, Cohen RD, Rubin DT, Pekow JR, Weber CR, Xiao SY, Hart J, Segal J, Setia N.

Hum Pathol. 2019 Jul;89:44-50. doi: 10.1016/j.humpath.2019.04.013. Epub 2019 May 2.

PMID:
31054900
7.

Renin-angiotensin system promotes colonic inflammation by inducing TH17 activation via JAK2/STAT pathway.

He L, Du J, Chen Y, Liu C, Zhou M, Adhikari S, Rubin DT, Pekow J, Li YC.

Am J Physiol Gastrointest Liver Physiol. 2019 Jun 1;316(6):G774-G784. doi: 10.1152/ajpgi.00053.2019. Epub 2019 Apr 17.

PMID:
30995068
8.

IBD-associated Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared With Sporadic Colon Cancers.

Pekow J, Hernandez K, Meckel K, Deng Z, Haider HI, Khalil A, Zhang C, Talisila N, Siva S, Jasmine F, Li YC, Rubin DT, Hyman N, Bissonnette M, Weber C, Kibriya MG.

J Crohns Colitis. 2019 Jul 25;13(7):884-893. doi: 10.1093/ecco-jcc/jjz014.

PMID:
30753380
9.

Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease.

Ollech JE, Aharoni-Golan M, Weisshof R, Normatov I, Sapp AR, Kalakonda A, Israel A, Glick LR, Karrison T, Dalal SR, Sakuraba A, Cohen RD, Rubin DT, Pekow J.

Gastrointest Endosc. 2019 Aug;90(2):269-275. doi: 10.1016/j.gie.2019.01.029. Epub 2019 Feb 6.

10.

Real-World Experience with Tofacitinib in IBD at a Tertiary Center.

Weisshof R, Aharoni Golan M, Sossenheimer PH, El Jurdi K, Ollech JE, Pekow J, Cohen RD, Sakuraba A, Dalal S, Rubin DT.

Dig Dis Sci. 2019 Jul;64(7):1945-1951. doi: 10.1007/s10620-019-05492-y. Epub 2019 Feb 7.

PMID:
30734234
11.

Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe.

Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT.

J Crohns Colitis. 2019 Sep 19;13(9):1105-1110. doi: 10.1093/ecco-jcc/jjz032.

PMID:
30726894
12.

Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases.

Buisson A, Mak WY, Andersen MJ, Lei D, Kahn SA, Pekow J, Cohen RD, Zmeter N, Pereira B, Rubin DT.

J Crohns Colitis. 2019 Aug 14;13(8):1012-1024. doi: 10.1093/ecco-jcc/jjz023.

PMID:
30726887
13.

Impact of Angiotensin II Signaling Blockade on Clinical Outcomes in Patients with Inflammatory Bowel Disease.

Jacobs JD, Wagner T, Gulotta G, Liao C, Li YC, Bissonnette M, Pekow J.

Dig Dis Sci. 2019 Jul;64(7):1938-1944. doi: 10.1007/s10620-019-5474-4. Epub 2019 Feb 6.

PMID:
30725290
14.

Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection.

Paknikar R, Pekow J.

Surg Infect (Larchmt). 2018 Nov/Dec;19(8):785-791. doi: 10.1089/sur.2018.221. Epub 2018 Oct 9. Review.

PMID:
30300561
15.

Correction to: Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study.

Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT.

Dig Dis Sci. 2018 Oct;63(10):2815. doi: 10.1007/s10620-018-5249-3.

PMID:
30136047
16.

A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease.

Anyane-Yeboa A, Yamada A, Haider H, Wang Y, Komaki Y, Komaki F, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A.

Aliment Pharmacol Ther. 2018 Nov;48(9):933-940. doi: 10.1111/apt.14951. Epub 2018 Aug 20.

17.

Identification of novel mRNAs and lncRNAs associated with mouse experimental colitis and human inflammatory bowel disease.

Rankin CR, Theodorou E, Man Law IK, Rowe L, Kokkotou E, Pekow J, Wang J, Martín MG, Pothoulakis C, Padua D.

Am J Physiol Gastrointest Liver Physiol. 2018 Nov 1;315(5):G722-G733. doi: 10.1152/ajpgi.00077.2018. Epub 2018 Jun 28.

18.

Tryptophan Metabolism through the Kynurenine Pathway is Associated with Endoscopic Inflammation in Ulcerative Colitis.

Sofia MA, Ciorba MA, Meckel K, Lim CK, Guillemin GJ, Weber CR, Bissonnette M, Pekow JR.

Inflamm Bowel Dis. 2018 Jun 8;24(7):1471-1480. doi: 10.1093/ibd/izy103.

19.

Lack of Difference in Treatment Patterns and Clinical Outcomes Between Black and White Patients With Inflammatory Bowel Disease.

Barnes EL, Kochar B, Long MD, Pekow J, Ananthakrishnan A, Anyane-Yeboa A, Martin C, Galanko J, Herfarth HH, Kappelman MD, Sandler RS.

Inflamm Bowel Dis. 2018 Nov 29;24(12):2634-2640. doi: 10.1093/ibd/izy179.

PMID:
29788063
20.

Increased mucosal expression of miR-215 precedes the development of neoplasia in patients with long-standing ulcerative colitis.

Pekow J, Meckel K, Dougherty U, Haider HI, Deng Z, Hart J, Rubin DT, Bissonnette M.

Oncotarget. 2018 Apr 17;9(29):20709-20720. doi: 10.18632/oncotarget.25065. eCollection 2018 Apr 17.

21.

Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy.

Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J.

Inflamm Bowel Dis. 2018 May 18;24(6):1291-1297. doi: 10.1093/ibd/izx105.

PMID:
29506124
22.

Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.

Mak WY, Buisson A, Andersen MJ Jr, Lei D, Pekow J, Cohen RD, Kahn SA, Pereira B, Rubin DT.

Dig Dis Sci. 2018 May;63(5):1294-1301. doi: 10.1007/s10620-018-4980-0. Epub 2018 Feb 22.

PMID:
29468374
23.

The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.

Yamada A, Komaki Y, Patel N, Komaki F, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A.

Inflamm Bowel Dis. 2018 Feb 15;24(3):502-509. doi: 10.1093/ibd/izx054.

PMID:
29462385
24.

Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study.

Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT.

Dig Dis Sci. 2018 Apr;63(4):1016-1024. doi: 10.1007/s10620-018-4941-7. Epub 2018 Feb 8. Erratum in: Dig Dis Sci. 2018 Oct;63(10):2815.

PMID:
29417331
25.

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.

Christensen B, Micic D, Gibson PR, Yarur A, Bellaguarda E, Corsello P, Gaetano JN, Kinnucan J, Rao VL, Reddy S, Singh S, Pekow J, Rubin DT.

Aliment Pharmacol Ther. 2018 Mar;47(6):753-762. doi: 10.1111/apt.14525. Epub 2018 Jan 29.

26.

Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease.

Micic D, Gaetano JN, Rubin JN, Cohen RD, Sakuraba A, Rubin DT, Pekow J.

PLoS One. 2017 Aug 24;12(8):e0182900. doi: 10.1371/journal.pone.0182900. eCollection 2017.

27.

Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon.

Krugliak Cleveland N, Rubin DT, Hart J, Weber CR, Meckel K, Tran AL, Aelvoet AS, Pan I, Gonsalves A, Gaetano JN, Williams KM, Wroblewski K, Jabri B, Pekow J.

Clin Gastroenterol Hepatol. 2018 Jan;16(1):68-74. doi: 10.1016/j.cgh.2017.07.023. Epub 2017 Jul 26.

28.

Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab.

Yamada A, Komaki Y, Patel N, Komaki F, Aelvoet AS, Tran AL, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A.

Am J Gastroenterol. 2017 Sep;112(9):1423-1429. doi: 10.1038/ajg.2017.201. Epub 2017 Jul 18.

PMID:
28719595
29.

miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD.

Pekow J, Meckel K, Dougherty U, Huang Y, Chen X, Almoghrabi A, Mustafi R, Ayaloglu-Butun F, Deng Z, Haider HI, Hart J, Rubin DT, Kwon JH, Bissonnette M.

Clin Cancer Res. 2017 Sep 1;23(17):5281-5291. doi: 10.1158/1078-0432.CCR-17-0171. Epub 2017 Jun 9.

30.

miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling.

Pekow J, Hutchison AL, Meckel K, Harrington K, Deng Z, Talasila N, Rubin DT, Hanauer SB, Hurst R, Umanskiy K, Fichera A, Hart J, Dinner AR, Bissonnette M.

Inflamm Bowel Dis. 2017 Aug;23(8):1328-1337. doi: 10.1097/MIB.0000000000001104.

31.

The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.

Ananthakrishnan AN, Sakuraba A, Barnes EL, Pekow J, Raffals L, Long MD, Sandler RS.

Aliment Pharmacol Ther. 2017 Jul;46(2):162-168. doi: 10.1111/apt.14125. Epub 2017 May 3.

32.

Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease.

Siva S, Rubin DT, Gulotta G, Wroblewski K, Pekow J.

Inflamm Bowel Dis. 2017 Jan;23(1):152-157. doi: 10.1097/MIB.0000000000000989.

33.

Northern Latitude but Not Season Is Associated with Increased Rates of Hospitalizations Related to Inflammatory Bowel Disease: Results of a Multi-Year Analysis of a National Cohort.

Stein AC, Gaetano JN, Jacobs J, Kunnavakkam R, Bissonnette M, Pekow J.

PLoS One. 2016 Aug 31;11(8):e0161523. doi: 10.1371/journal.pone.0161523. eCollection 2016.

34.

ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet-associated Colon Cancer.

Mustafi R, Dougherty U, Mustafi D, Ayaloglu-Butun F, Fletcher M, Adhikari S, Sadiq F, Meckel K, Haider HI, Khalil A, Pekow J, Konda V, Joseph L, Hart J, Fichera A, Li YC, Bissonnette M.

Clin Cancer Res. 2017 Jan 15;23(2):549-561. doi: 10.1158/1078-0432.CCR-15-3140. Epub 2016 Aug 3.

35.

Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis.

Meckel K, Li YC, Lim J, Kocherginsky M, Weber C, Almoghrabi A, Chen X, Kaboff A, Sadiq F, Hanauer SB, Cohen RD, Kwon J, Rubin DT, Hanan I, Sakuraba A, Yen E, Bissonnette M, Pekow J.

Am J Clin Nutr. 2016 Jul;104(1):113-20. doi: 10.3945/ajcn.115.123786. Epub 2016 Jun 8.

36.

Activation of the Renin-Angiotensin System Promotes Colitis Development.

Shi Y, Liu T, He L, Dougherty U, Chen L, Adhikari S, Alpert L, Zhou G, Liu W, Wang J, Deb DK, Hart J, Liu SQ, Kwon J, Pekow J, Rubin DT, Zhao Q, Bissonnette M, Li YC.

Sci Rep. 2016 Jun 8;6:27552. doi: 10.1038/srep27552.

37.

The features of mucosa-associated microbiota in primary sclerosing cholangitis.

Torres J, Bao X, Goel A, Colombel JF, Pekow J, Jabri B, Williams KM, Castillo A, Odin JA, Meckel K, Fasihuddin F, Peter I, Itzkowitz S, Hu J.

Aliment Pharmacol Ther. 2016 Apr;43(7):790-801. doi: 10.1111/apt.13552. Epub 2016 Feb 9.

38.

Education and Imaging. Gastroenterology: Small bowel obstruction due to multiple spontaneous intramural duodenal hematomas.

Jacobs J, Pekow J.

J Gastroenterol Hepatol. 2015 Aug;30(8):1225. doi: 10.1111/jgh.12919. No abstract available.

PMID:
26201666
39.

Parastomal Variceal Bleeding Attributed to Obstructive Pathology Successfully Treated by Percutaneous Variceal Embolization.

Tomizawa Y, Sakuraba A, Pekow J.

ACG Case Rep J. 2014 Jul 8;1(4):217-9. doi: 10.14309/crj.2014.58. eCollection 2014 Jul.

40.

Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.

Bellaguarda E, Keyashian K, Pekow J, Rubin DT, Cohen RD, Sakuraba A.

Clin Gastroenterol Hepatol. 2015 Nov;13(11):1919-25. doi: 10.1016/j.cgh.2015.05.022. Epub 2015 May 19.

41.

The emerging role of miRNAs in inflammatory bowel disease: a review.

Chapman CG, Pekow J.

Therap Adv Gastroenterol. 2015 Jan;8(1):4-22. doi: 10.1177/1756283X14547360. Review.

42.

Tumor suppressors miR-143 and miR-145 and predicted target proteins API5, ERK5, K-RAS, and IRS-1 are differentially expressed in proximal and distal colon.

Pekow J, Meckel K, Dougherty U, Butun F, Mustafi R, Lim J, Crofton C, Chen X, Joseph L, Bissonnette M.

Am J Physiol Gastrointest Liver Physiol. 2015 Feb 1;308(3):G179-87. doi: 10.1152/ajpgi.00208.2014. Epub 2014 Dec 4.

43.

The renin-angiotensin system mediates EGF receptor-vitamin d receptor cross-talk in colitis-associated colon cancer.

Dougherty U, Mustafi R, Sadiq F, Almoghrabi A, Mustafi D, Kreisheh M, Sundaramurthy S, Liu W, Konda VJ, Pekow J, Khare S, Hart J, Joseph L, Wyrwicz A, Karczmar GS, Li YC, Bissonnette M.

Clin Cancer Res. 2014 Nov 15;20(22):5848-5859. doi: 10.1158/1078-0432.CCR-14-0209. Epub 2014 Sep 11.

44.

Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital.

Sofia MA, Rubin DT, Hou N, Pekow J.

Dig Dis Sci. 2014 Sep;59(9):2228-35. doi: 10.1007/s10620-014-3160-0. Epub 2014 Apr 22.

45.

Is RXRα crucially involved in intestinal inflammation?

Pekow J, Bissonnette M.

Dig Dis Sci. 2014 Apr;59(4):702-3. doi: 10.1007/s10620-013-2990-5. Epub 2014 Jan 16. No abstract available.

46.
47.

Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis.

Liu W, Chen Y, Golan MA, Annunziata ML, Du J, Dougherty U, Kong J, Musch M, Huang Y, Pekow J, Zheng C, Bissonnette M, Hanauer SB, Li YC.

J Clin Invest. 2013 Sep;123(9):3983-96. doi: 10.1172/JCI65842. Epub 2013 Aug 15.

48.

Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions.

Pekow J, Dougherty U, Huang Y, Gometz E, Nathanson J, Cohen G, Levy S, Kocherginsky M, Venu N, Westerhoff M, Hart J, Noffsinger AE, Hanauer SB, Hurst RD, Fichera A, Joseph LJ, Liu Q, Bissonnette M.

Inflamm Bowel Dis. 2013 Mar;19(3):461-70. doi: 10.1097/MIB.0b013e3182802bac.

49.

Association between higher predicted serum vitamin D levels and reduced incidence of inflammatory bowel diseases.

Pekow J, Li YC, Hanauer SB.

Gastroenterology. 2012 Sep;143(3):e28. doi: 10.1053/j.gastro.2012.06.046. Epub 2012 Jul 26. No abstract available.

PMID:
22841731
50.

Chitinase 3-like-1 expression in colonic epithelial cells as a potentially novel marker for colitis-associated neoplasia.

Chen CC, Pekow J, Llado V, Kanneganti M, Lau CW, Mizoguchi A, Mino-Kenudson M, Bissonnette M, Mizoguchi E.

Am J Pathol. 2011 Sep;179(3):1494-503. doi: 10.1016/j.ajpath.2011.05.038. Epub 2011 Jul 16.

Supplemental Content

Support Center